バイオテクノロジー受託製造市場 : 2028年までの世界予測

Report Overview

The biotechnology contract manufacturing market is estimated to reach USD 24.8 billion by 2028 from USD 16.6 billion in 2023, at a CAGR of 8.3% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the increasing partnerships and collaborations between pharmaceutical companies and biologics contract manufacturers. For instance, In January 2023, Catalent (US) entered into an agreement with Sarepta Therapeutics, Inc. (US) for manufacturing of Sarepta’s most advanced gene therapy candidate, delandistrogene moxeparvovec (SRP-9001) for the treatment of Duchenne muscular dystrophy.  Similarly, In December 2022, Merck KGaA (Germany) and Synplogen (Japan) entered into an agreement to accelerate the development and manufacturing of viral vector-based gene therapy applications.

“The monoclonal antibodies segment accounted for the largest share by molecule type during the forecast period.”

In 2022, the monoclonal antibodies segment accounted for the largest share by molecules in the global biotechnology contract manufacturing market. The large share of this segment is attributed to the rising prevalence of diseases, increasing government initiatives for the development of monoclonal antibody drugs, and the growing number of mAb product candidates currently in the clinical pipeline. 

 “Europe: The second largest region in the biotechnology contract manufacturing market”

Europe accounted for the second-largest market for biotechnology contract manufacturing market after North America. The European biotechnology contract manufacturing market has experienced substantial growth in recent years, driven by various factors such as increasing investments for the development of biologics such as monoclonal antibodies and cell & gene therapies and biomanufacturing capacity expansions. Europe is at the forefront of developing and adopting emerging technologies in the field of biotechnology contract manufacturing market. In March 2023, Lonza completed its cGMP clinical and commercial manufacturing site, which is dedicated to large-scale commercial drug product manufacturing.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side – 70% and Demand Side – 30%
• By Designation: Managers – 45%, CXO and Directors – 30%, and Executives – 25%
• By Region: North America – 40%, Europe – 25%, Asia-Pacific – 20%, Latin America – 10% and Middle East & Africa – 5%
List of Companies Profiled in the Report:
• Lonza (Switzerland)
• Thermo Fisher Scientific Inc. (US)
• Catalent, Inc. (US)
• Samsung Biologics (South Korea)
• WuXi Biologics (China)
• Boehringer Ingelheim International GmbH (Germany)
• FUJIFILM Holdings Corporation (Japan)
• AbbVie, Inc. (US)
• Eurofins Scientific (Luxembourg)
• GenScript Biotech Corporation (US)
• AGC, Inc. (Japan)
• Merck KGaA (Germany)
• JSR Corporation (Japan)
• Stelis (India)
• Recipharm AB (Sweden)
• Emergent (US)
• Shanghai Fosun Pharmaceutical Co., Ltd. (China)
• LOTTE BIOLOGICS (South Korea)
• Hepalink Group (China)
• Curia Global, Inc. (US)
• JRS Pharma (Germany)
• MINAPHARM Pharmaceuticals (Egypt)
• Rentschler Biopharma SE (Germany)
• Avid Bioservices, Inc. (US)
• Abzena Ltd. (US)
• Polyplus Transfection (Germany)
• Midas Pharma GmbH (Germany)
• MabPlex International Co., Ltd. (China)
• Asahi Kasei Corporation (Japan)

Research Coverage:

This report provides a detailed picture of the biotechnology contract manufacturing market. It aims to estimate the size and future growth potential of the market across different segments such as the service, type, scale of operation, source, molecule type, therapeutic area, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Increasing demand for biologics & biosimilars, Increased biologics outsourcing trend among biopharmaceutical companies, Increased focus on personalized medicine, Increasing partnerships and collaborations between pharmaceutical companies and biologics CDMOs), restraints (intellectual property rights issues), opportunities (Rising demand for cell & gene therapy, biologics contract manufacturing market expansions in emerging countries, expansion of biologics manufacturing capacities by CMOs, strong emphasis on drug development), and challenges (challenges to meet reformed regulations) influencing the growth of the market.
• Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the biotechnology contract manufacturing market
• Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the biotechnology contract manufacturing market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), WuXi Biologics (China), AbbVie, Inc. (US), and others in the market.

Table of Contents

1 INTRODUCTION 39

1.1 STUDY OBJECTIVES 39
1.2 MARKET DEFINITION AND SCOPE 39
1.2.1 INCLUSIONS AND EXCLUSIONS 40
1.2.2 MARKETS COVERED 41
1.2.3 YEARS CONSIDERED 41
1.3 CURRENCY 42
1.4 STAKEHOLDERS 42
1.5 LIMITATIONS 42
1.6 RECESSION IMPACT 43

2 RESEARCH METHODOLOGY 44

2.1 RESEARCH DATA 44
FIGURE 1 RESEARCH DESIGN 44
2.1.1 SECONDARY DATA 45
2.1.2 PRIMARY DATA 46
FIGURE 2 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: BREAKDOWN OF PRIMARIES 46
2.2 MARKET SIZE ESTIMATION 47
FIGURE 3 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 47
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 – REVENUE SHARE ANALYSIS, 2022 48
FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS, 2022 49
2.2.1 INSIGHTS FROM PRIMARIES 50
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 50
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 50
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 51
FIGURE 8 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: CAGR PROJECTIONS 52
FIGURE 9 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 52
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 53
FIGURE 10 DATA TRIANGULATION METHODOLOGY 53
2.5 RESEARCH ASSUMPTIONS 54
2.6 RISK ANALYSIS 54
2.7 RECESSION IMPACT ANALYSIS 54
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH) 54
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 55
TABLE 3 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION) 55

3 EXECUTIVE SUMMARY 57

FIGURE 11 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023 VS. 2028 (USD MILLION) 57
FIGURE 12 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 58
FIGURE 13 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023 VS. 2028 (USD MILLION) 58
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET 59

4 PREMIUM INSIGHTS 61

4.1 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET OVERVIEW 61
FIGURE 15 RISING APPROVALS OF BIOLOGICS TO DRIVE MARKET 61
4.2 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SHARE, BY SCALE OF OPERATION & COUNTRY (2022) 62
FIGURE 16 COMMERCIAL OPERATIONS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022 62
4.3 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SHARE, BY THERAPEUTIC AREA, 2023 VS. 2028 62
FIGURE 17 ONCOLOGY SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2028 62
4.4 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023 VS. 2028 (USD MILLION) 63
FIGURE 18 PHARMACEUTICAL MANUFACTURING SERVICES SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2028 63
4.5 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 64
FIGURE 19 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 64

5 MARKET OVERVIEW 65

5.1 INTRODUCTION 65
5.2 MARKET DYNAMICS 65
FIGURE 20 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 65
TABLE 4 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: IMPACT ANALYSIS 66
5.2.1 DRIVERS 66
5.2.1.1 Rising demand for biologics and biosimilars 66
FIGURE 21 NUMBER OF APPROVED BIOLOGICS, 2015–2022 67
FIGURE 22 US: NUMBER OF APPROVED AND LAUNCHED BIOSIMILARS, 2015–2022 67
5.2.1.2 Increasing outsourcing of biologics manufacturing among biopharmaceutical companies 68
5.2.1.3 Growing focus on personalized medicine 68
FIGURE 23 PERSONALIZED MEDICINES (% OF ALL FDA-APPROVED DRUGS), 2015–2022 69
5.2.1.4 Increasing collaborations between pharmaceutical companies and biologics CMOs 69
5.2.1.5 Advancements in manufacturing technologies 70
5.2.2 RESTRAINTS 70
5.2.2.1 Intellectual property rights issues 70
5.2.3 OPPORTUNITIES 71
5.2.3.1 Rising demand for cell and gene therapies 71
TABLE 5 LIST OF EXPANSIONS BY TOP COMPANIES 71
5.2.3.2 Significant growth opportunities offered by emerging countries 72
5.2.3.3 Expansion of biologics manufacturing capacities by CMOs 72
5.2.3.4 Strong emphasis on drug development 73
TABLE 6 LIST OF KEY BIOLOGICS FACING PATENT EXPIRY 74
5.2.4 CHALLENGES 74
5.2.4.1 Complying with regulatory reforms 74
5.3 VALUE CHAIN ANALYSIS 75
FIGURE 24 VALUE CHAIN ANALYSIS OF BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: MANUFACTURING AND DISTRIBUTION PHASES ADD MAXIMUM VALUE 75
5.4 ECOSYSTEM ANALYSIS 76
FIGURE 25 ECOSYSTEM ANALYSIS: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET 76
TABLE 7 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: ROLE IN ECOSYSTEM 76
5.5 PORTER’S FIVE FORCES ANALYSIS 78
TABLE 8 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS 78
5.5.1 THREAT OF NEW ENTRANTS 78
5.5.2 THREAT OF SUBSTITUTES 78
5.5.3 BARGAINING POWER OF SUPPLIERS 78
5.5.4 BARGAINING POWER OF BUYERS 78
5.5.5 INTENSITY OF COMPETITIVE RIVALRY 79
5.6 TECHNOLOGY ANALYSIS 79
5.7 REGULATORY ANALYSIS 80
5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 13 REGULATORY SCENARIOS ACROSS DIFFERENT COUNTRIES/REGIONS 83
5.8 KEY CONFERENCES AND EVENTS IN 2023–2024 85
TABLE 14 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 85
5.9 KEY STAKEHOLDERS AND BUYING CRITERIA 86
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS 86
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOTECHNOLOGY CMO SERVICES 86
5.9.2 BUYING CRITERIA 86
FIGURE 27 KEY BUYING CRITERIA FOR END USERS 86
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 87

6 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE 88

6.1 INTRODUCTION 89
TABLE 15 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 89
6.2 MANUFACTURING 89
6.2.1 SHIFT TOWARD SINGLE-USE TECHNOLOGY TO DRIVE MARKET 89
TABLE 16 BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 90
TABLE 17 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 18 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 19 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 20 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
6.3 FORMULATION & FILL-FINISH 92
6.3.1 MOST CRITICAL ASPECT OF BIOLOGICS MANUFACTURING 92
TABLE 21 BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 93
TABLE 22 NORTH AMERICA: BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 23 EUROPE: BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 24 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 25 LATIN AMERICA: BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
6.4 PACKAGING & LABELING 95
6.4.1 FINAL CHECKPOINT BEFORE PRODUCT REACHES PATIENT 95
TABLE 26 BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 96
TABLE 27 NORTH AMERICA: BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 28 EUROPE: BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 29 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 30 LATIN AMERICA: BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
6.5 OTHER SERVICES 98
TABLE 31 OTHER BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 98
TABLE 32 NORTH AMERICA: OTHER BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 33 EUROPE: OTHER BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 34 ASIA PACIFIC: OTHER BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 35 LATIN AMERICA: OTHER BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100

7 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE 101

7.1 INTRODUCTION 102
TABLE 36 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 102
7.2 BIOLOGIC DRUG SUBSTANCE MANUFACTURING 102
7.2.1 INCREASING DEMAND FOR BIOTECHNOLOGY PRODUCTS TO DRIVE MARKET 102
TABLE 37 BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 103
TABLE 38 NORTH AMERICA: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 39 EUROPE: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 40 ASIA PACIFIC: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 41 LATIN AMERICA: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
7.3 BIOLOGIC DRUG PRODUCT MANUFACTURING 105
7.3.1 INCREASING R&D COST AND PROCESS COMPLEXITY PROMPTED SHIFT TOWARD CONTRACT MANUFACTURING FOR BIOLOGIC DRUG PRODUCTS 105
TABLE 42 BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 106
TABLE 43 NORTH AMERICA: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 44 EUROPE: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 45 ASIA PACIFIC: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 46 LATIN AMERICA: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108

8 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION 109

8.1 INTRODUCTION 110
TABLE 47 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 110
8.2 COMMERCIAL OPERATIONS 110
8.2.1 INCREASING APPROVALS OF BIOLOGICS TO SUPPORT MARKET GROWTH 110
TABLE 48 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 49 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 50 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 51 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 52 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 113
8.3 CLINICAL OPERATIONS 113
8.3.1 INCREASING NUMBER OF CLINICAL TRIALS FOR TARGETED THERAPIES TO DRIVE MARKET 113
TABLE 53 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION) 114
TABLE 54 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 55 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 56 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 57 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 116

9 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE 117

9.1 INTRODUCTION 118
TABLE 58 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 118
9.2 MAMMALIAN EXPRESSION SYSTEMS 118
9.2.1 VERSATILE THERAPEUTIC DIVERSITY TO DRIVE MARKET 118
TABLE 59 TYPES OF MAMMALIAN EXPRESSION SYSTEMS 119
TABLE 60 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 119
TABLE 61 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 62 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 63 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 64 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 121
9.3 NON-MAMMALIAN EXPRESSION SYSTEMS 121
9.3.1 INCREASING DEMAND FOR BIOLOGICS VACCINES TO SUPPORT MARKET GROWTH 121
TABLE 65 TYPES OF MICROBIAL EXPRESSION SYSTEMS AND THEIR APPLICATIONS 122
TABLE 66 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 123
TABLE 67 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 68 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 69 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 70 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 125

10 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE 126

10.1 INTRODUCTION 127
TABLE 71 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 127
10.2 MONOCLONAL ANTIBODIES 127
10.2.1 GROWING APPROVALS FOR MABS TO PROPEL MARKET 127
FIGURE 28 NUMBER OF APPROVED MONOCLONAL ANTIBODIES, 2010–2022 128
TABLE 72 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 128
TABLE 73 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 74 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 75 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 76 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 130
10.3 CELL & GENE THERAPIES 130
10.3.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET 130
TABLE 77 FDA-APPROVED CAR T-CELL THERAPIES 131
TABLE 78 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY REGION, 2021–2028 (USD MILLION) 132
TABLE 79 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 80 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 81 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 82 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION) 134
10.4 ANTIBODY-DRUG CONJUGATES 134
10.4.1 INCREASING INVESTMENTS IN BIOLOGICS TO SUPPORT MARKET GROWTH 134
TABLE 83 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY REGION, 2021–2028 (USD MILLION) 135
TABLE 84 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 85 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 86 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 87 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2021–2028 (USD MILLION) 137
10.5 VACCINES 137
10.5.1 INCREASING DEMAND FOR VACCINES TO DRIVE MARKET 137
TABLE 88 NIH FUNDING FOR VACCINE RESEARCH, 2018–2022 (USD MILLION) 137
TABLE 89 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION) 138
TABLE 90 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 91 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 92 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 93 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 140
10.6 THERAPEUTIC PEPTIDES & PROTEINS 140
10.6.1 INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS TO SUPPORT MARKET GROWTH 140
TABLE 94 EXAMPLES OF PEPTIDE THERAPEUTICS 141
TABLE 95 COMMERCIALIZED RECOMBINANT PROTEINS USED IN MEDICINE 141
TABLE 96 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2021–2028 (USD MILLION) 142
TABLE 97 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 98 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 99 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 100 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 144
10.7 OTHER MOLECULE TYPES 144
TABLE 101 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULE TYPES, BY REGION, 2021–2028 (USD MILLION) 145
TABLE 102 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULE TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 103 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULE TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 104 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULE TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 105 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULE TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 147

11 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA 148

11.1 INTRODUCTION 149
TABLE 106 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 149
11.2 ONCOLOGY 149
11.2.1 INCREASED APPROVALS AND LAUNCH OF BIOLOGICS FOR ONCOLOGY TO DRIVE MARKET 149
TABLE 107 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 151
TABLE 108 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 109 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 152
TABLE 110 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 152
TABLE 111 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 153
11.3 AUTOIMMUNE DISEASES 153
11.3.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES TO DRIVE MARKET 153
TABLE 112 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2021–2028 (USD MILLION) 154
TABLE 113 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 114 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 155
TABLE 115 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 155
TABLE 116 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 156
11.4 METABOLIC DISEASES 156
11.4.1 INCREASING PREVALENCE OF METABOLIC DISEASES TO DRIVE ADOPTION OF BIOLOGICS 156
TABLE 117 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY REGION, 2021–2028 (USD MILLION) 157
TABLE 118 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 119 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 120 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 121 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 159
11.5 CARDIOVASCULAR DISEASES 159
11.5.1 DEVELOPMENT OF NEW TREATMENT OPTIONS TO SUPPORT MARKET GROWTH 159
TABLE 122 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION) 160
TABLE 123 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 124 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 125 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 126 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 162
11.6 NEUROLOGY 162
11.6.1 HIGH BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET 162
TABLE 127 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION) 163
TABLE 128 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 129 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 130 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 131 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 165
11.7 INFECTIOUS DISEASES 165
11.7.1 RISING EPIDEMIC OUTBREAKS TO SUPPORT MARKET GROWTH 165
TABLE 132 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 166
TABLE 133 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 166
TABLE 134 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 135 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 136 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 168
11.8 OTHER THERAPEUTIC AREAS 168
TABLE 137 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION) 169
TABLE 138 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 169
TABLE 139 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 140 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 141 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 171

12 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY REGION 172

12.1 INTRODUCTION 173
TABLE 142 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 173
12.2 NORTH AMERICA 173
FIGURE 29 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SNAPSHOT 174
TABLE 143 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 144 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 175
TABLE 145 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 176
TABLE 146 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 176
TABLE 147 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 177
TABLE 148 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 177
TABLE 149 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 178
12.2.1 US 178
12.2.1.1 Presence of large number of FDA-approved manufacturing facilities to favor market growth 178
TABLE 150 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 179
TABLE 151 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 179
TABLE 152 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 180
TABLE 153 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 180
TABLE 154 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 181
TABLE 155 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 181
12.2.2 CANADA 182
12.2.2.1 Rising government funding for drug development to support market growth 182
TABLE 156 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 182
TABLE 157 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 183
TABLE 158 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 183
TABLE 159 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 184
TABLE 160 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 184
TABLE 161 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 185
12.2.3 RECESSION IMPACT 185
12.3 EUROPE 186
TABLE 162 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 186
TABLE 163 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 187
TABLE 164 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 165 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 188
TABLE 166 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 188
TABLE 167 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 189
TABLE 168 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 189
12.3.1 GERMANY 190
12.3.1.1 Rapidly growing pharmaceutical market to drive market 190
TABLE 169 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 190
TABLE 170 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 171 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 191
TABLE 172 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 192
TABLE 173 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 192
TABLE 174 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 193
12.3.2 UK 193
12.3.2.1 Rising investments in drug development to favor market growth 193
TABLE 175 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 194
TABLE 176 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 194
TABLE 177 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 195
TABLE 178 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 195
TABLE 179 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 196
TABLE 180 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 196
12.3.3 FRANCE 197
12.3.3.1 Availability of funds from government and private organizations for domestic drug development to support market growth 197
TABLE 181 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 197
TABLE 182 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 183 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 198
TABLE 184 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 199
TABLE 185 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 199
TABLE 186 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 200
12.3.4 ITALY 200
12.3.4.1 Rising commercial drug development pipeline to drive market 200
TABLE 187 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 201
TABLE 188 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 189 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 202
TABLE 190 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 202
TABLE 191 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 203
TABLE 192 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 203
12.3.5 SPAIN 204
12.3.5.1 Rising R&D expenditure to propel market 204
TABLE 193 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 204
TABLE 194 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 195 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 205
TABLE 196 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 206
TABLE 197 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 206
TABLE 198 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 207
12.3.6 REST OF EUROPE 207
TABLE 199 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 208
TABLE 200 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 201 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 209
TABLE 202 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 209
TABLE 203 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 210
TABLE 204 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 210
12.3.7 RECESSION IMPACT 211

12.4 ASIA PACIFIC 211
FIGURE 30 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SNAPSHOT 212
TABLE 205 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 213
TABLE 206 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 213
TABLE 207 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 214
TABLE 208 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 214
TABLE 209 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 215
TABLE 210 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 215
TABLE 211 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 216
12.4.1 CHINA 216
12.4.1.1 Low manufacturing cost and high demand for medicines to favor market growth 216
TABLE 212 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 217
TABLE 213 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 217
TABLE 214 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 218
TABLE 215 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 218
TABLE 216 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 219
TABLE 217 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 219
12.4.2 JAPAN 220
12.4.2.1 Growing demand for biosimilars to drive growth 220
TABLE 218 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 220
TABLE 219 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 221
TABLE 220 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 221
TABLE 221 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 222
TABLE 222 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 222
TABLE 223 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 223
12.4.3 SOUTH KOREA 223
12.4.3.1 Increasing R&D activities for drug development to drive market 223
TABLE 224 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 224
TABLE 225 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 226 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 225
TABLE 227 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 225
TABLE 228 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 226
TABLE 229 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 226
12.4.4 INDIA 227
12.4.4.1 Increasing pharma R&D activities and government funding for biotechnology industry to support market growth 227
TABLE 230 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 227
TABLE 231 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 228
TABLE 232 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 228
TABLE 233 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 229
TABLE 234 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 229
TABLE 235 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 230
12.4.5 REST OF ASIA PACIFIC 230
TABLE 236 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 231
TABLE 237 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 231
TABLE 238 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 232
TABLE 239 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 232
TABLE 240 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 233
TABLE 241 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 233
12.4.6 RECESSION IMPACT 234
12.5 LATIN AMERICA 234
TABLE 242 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 234
TABLE 243 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 235
TABLE 244 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 235
TABLE 245 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 236
TABLE 246 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 236
TABLE 247 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 237
TABLE 248 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 237
12.5.1 BRAZIL 238
12.5.1.1 Growing pharmaceutical industry to drive market 238
TABLE 249 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 238
TABLE 250 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 239
TABLE 251 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 239
TABLE 252 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 240
TABLE 253 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 240
TABLE 254 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 241
12.5.2 REST OF LATIN AMERICA 241
TABLE 255 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 242
TABLE 256 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 242
TABLE 257 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 243
TABLE 258 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 243
TABLE 259 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 244
TABLE 260 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 244
12.5.3 RECESSION IMPACT 245
12.6 MIDDLE EAST & AFRICA 245
12.6.1 GROWING PHARMACEUTICALS INDUSTRY TO SUPPORT MARKET GROWTH 245
TABLE 261 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION) 246
TABLE 262 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 246
TABLE 263 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION) 247
TABLE 264 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION) 247
TABLE 265 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION) 248
TABLE 266 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 248
12.6.2 RECESSION IMPACT 249

13 COMPETITIVE LANDSCAPE 250

13.1 INTRODUCTION 250
FIGURE 31 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 251
13.2 REVENUE SHARE ANALYSIS 252
FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022 252
13.3 MARKET SHARE ANALYSIS 252
FIGURE 33 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022 253
TABLE 267 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DEGREE OF COMPETITION 253
13.4 COMPANY EVALUATION MATRIX 254
13.4.1 STARS 255
13.4.2 EMERGING LEADERS 255
13.4.3 PERVASIVE PLAYERS 255
13.4.4 PARTICIPANTS 255
FIGURE 34 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 256
13.5 COMPETITIVE BENCHMARKING 256
13.5.1 COMPANY FOOTPRINT ANALYSIS 256
TABLE 268 COMPANY FOOTPRINT ANALYSIS 256
13.5.2 COMPANY FOOTPRINT ANALYSIS, BY MOLECULE TYPE 258
TABLE 269 MOLECULE TYPE FOOTPRINT ANALYSIS OF COMPANIES 258
13.5.3 COMPANY FOOTPRINT ANALYSIS, BY REGION 259
TABLE 270 REGIONAL FOOTPRINT ANALYSIS OF COMPANIES 259
13.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES 261
13.6.1 PROGRESSIVE COMPANIES 261
13.6.2 STARTING BLOCKS 261
13.6.3 RESPONSIVE COMPANIES 261
13.6.4 DYNAMIC COMPANIES 261
FIGURE 35 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022 262
13.7 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 263
TABLE 271 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 263
TABLE 272 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS 264
13.8 COMPETITIVE SCENARIO AND TRENDS 264
13.8.1 DEALS 264
TABLE 273 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DEALS, JANUARY 2020–JULY 2023 264
13.8.2 OTHER DEVELOPMENTS 265
TABLE 274 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: OTHER DEVELOPMENTS, JANUARY 2020–JULY 2023 265

14 COMPANY PROFILES 266
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*

14.1 KEY PLAYERS 266
14.1.1 LONZA 266
TABLE 275 LONZA: BUSINESS OVERVIEW 266
FIGURE 36 LONZA: COMPANY SNAPSHOT (2022) 267
14.1.2 THERMO FISHER SCIENTIFIC INC. 272
TABLE 276 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 272
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 273
14.1.3 WUXI BIOLOGICS 276
TABLE 277 WUXI BIOLOGICS: BUSINESS OVERVIEW 276
FIGURE 38 WUXI BIOLOGICS: COMPANY SNAPSHOT (2022) 276
14.1.4 CATALENT, INC. 280
TABLE 278 CATALENT, INC.: BUSINESS OVERVIEW 280
FIGURE 39 CATALENT, INC.: COMPANY SNAPSHOT (2022) 281
14.1.5 SAMSUNG BIOLOGICS 286
TABLE 279 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW 286
FIGURE 40 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2022) 287
14.1.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 290
TABLE 280 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW 290
FIGURE 41 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022) 291
14.1.7 FUJIFILM HOLDINGS CORPORATION 294
TABLE 281 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW 294
FIGURE 42 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022) 295
14.1.8 ABBVIE INC. 298
TABLE 282 ABBVIE INC.: BUSINESS OVERVIEW 298
FIGURE 43 ABBVIE INC.: COMPANY SNAPSHOT (2022) 298
14.1.9 EUROFINS SCIENTIFIC 300
TABLE 283 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 300
FIGURE 44 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022) 301
14.1.10 GENSCRIPT BIOTECH CORPORATION 303
TABLE 284 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW 303
FIGURE 45 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2022) 304
14.1.11 AGC INC. 307
TABLE 285 AGC INC.: BUSINESS OVERVIEW 307
FIGURE 46 AGC INC.: COMPANY SNAPSHOT (2022) 308
14.1.12 MERCK KGAA 311
TABLE 286 MERCK KGAA: BUSINESS OVERVIEW 311
FIGURE 47 MERCK KGAA: COMPANY SNAPSHOT (2022) 312
14.1.13 JSR CORPORATION 314
TABLE 287 JSR CORPORATION: BUSINESS OVERVIEW 314
FIGURE 48 JSR CORPORATION: COMPANY SNAPSHOT (2022) 315
14.2 OTHER PLAYERS 317
14.2.1 STELIS 317
14.2.2 RECIPHARM AB 317
14.2.3 EMERGENT 318
14.2.4 SHANGHAI FOSUN PHARMACEUTICAL CO., LTD. 319
14.2.5 LOTTE BIOLOGICS 320
14.2.6 HEPALINK GROUP 321
14.2.7 CURIA GLOBAL, INC. 322
14.2.8 JRS PHARMA 322
14.2.9 MINAPHARM PHARMACEUTICALS 323
14.2.10 RENTSCHLER BIOPHARMA SE 323
14.2.11 AVID BIOSERVICES, INC. 324
14.2.12 ABZENA LTD. 325
14.2.13 POLYPLUS TRANSFECTION 325
14.2.14 MIDAS PHARMA GMBH 326
14.2.15 MABPLEX INTERNATIONAL CO., LTD. 326
14.2.16 ASAHI KASEI CORPORATION 327
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.

15 APPENDIX 328

15.1 DISCUSSION GUIDE 328
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 333
15.3 CUSTOMIZATION OPTIONS 335
15.4 RELATED REPORTS 335
15.5 AUTHOR DETAILS 336